Jeffrey Mitchell
About Jeffrey Mitchell
Jeffrey Mitchell is a Principal Scientist of Protein Expression at Generate Biomedicines, Inc., with a strong background in protein expression and metabolic engineering. He has co-authored a patent and published significant research in the field, including studies on oncogenic signaling networks and monoclonal antibody optimization.
Current Role at Generate Biomedicines
Jeffrey Mitchell serves as the Principal Scientist of Protein Expression at Generate Biomedicines, Inc. since 2022. In this role, he focuses on advancing protein expression technologies and methodologies. His work contributes to the development of innovative biomedicines, leveraging his extensive experience in protein engineering and cell line development.
Previous Experience at Pfizer
Prior to his current position, Jeffrey Mitchell worked at Pfizer as a Senior Scientist of Cell Line Development from 2008 to 2022. During his 14 years at Pfizer in Andover, Massachusetts, he specialized in the development of cell lines for biopharmaceutical production. His research included significant contributions to the understanding of signaling networks related to oncogenic EGFR and c-Met.
Research Contributions and Publications
Jeffrey Mitchell has co-authored a United States patent (US 10,738,334 B2) related to cells with reduced BCAT1. He has published research on the metabolic engineering of Chinese hamster ovary cells, focusing on the reduction of growth inhibitors in fed-batch cultures. His work has appeared in notable journals, including the Proceedings of the National Academy of Sciences and Cell, highlighting his contributions to the field of cancer research and protein engineering.
Educational Background
Jeffrey Mitchell holds a Master of Science (MS) in Plant Molecular Biology and a Bachelor of Arts (BA) in Plant Biology, both from the University of New Hampshire. His academic training provided a strong foundation in molecular biology, which he has applied throughout his career in protein expression and cell line development.
Early Career at Cell Signaling Technology
Jeffrey Mitchell began his career as a Research Associate at Cell Signaling Technology (CST) from 2005 to 2006. This role allowed him to gain valuable experience in the field of signaling pathways and cellular processes, which he later applied in his research on oncogenic kinases and their implications in cancer.